# Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a
Ticker: RIGL
Company: Rigel Pharmaceuticals
Source: Rigel Pharmaceuticals
Published: 2026-07-28 12:05 EST
Original Source URL: https://www.rigel.com/investors/news-events/press-releases/detail/443/rigel-announces-conference-call-and-webcast-to-report
## Summary

, /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management...

## Article Body
, /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and will be accessible from the Investor Relations section of the company's website at www.rigel.com . The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com .

Contact for Investors & Media: Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 ir@rigel.com

Media: David Rosen Argot Partners Phone: 646.461.6387 Email: david.rosen@argotpartners.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financial-results-302835770.html

SOURCE Rigel Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-28 12:05 EST — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a) — Source: Rigel Pharmaceuticals
- 2026-07-01 12:05 EST — [Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer](https://biopharmsignal.com/news/RIGL/rigel-appoints-board-member-alison-l-hannah-m-d-as-chief-medical-officer-c2f47409) — Source: Rigel Pharmaceuticals
- 2026-06-16 20:01 EST — [Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)](https://biopharmsignal.com/news/RIGL/rigel-announces-closing-of-licensing-agreement-for-veppanu-vepdegestrant-31709183) — Source: Rigel Pharmaceuticals
- 2026-05-27 12:05 EST — [Rigel to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RIGL/rigel-to-present-at-the-jefferies-global-healthcare-conference) — Source: Rigel Pharmaceuticals
- 2026-05-21 21:17 EST — [Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress](https://biopharmsignal.com/news/RIGL/rigel-announces-oral-and-poster-presentations-at-the-2026-asco-annual-meeting-and-eha2026-congress) — Source: Rigel Pharmaceuticals
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)
- 2026-07-28 12:00 EST — UNH — [Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer](https://biopharmsignal.com/news/UNH/corbus-pharmaceuticals-announces-fda-clearance-to-initiate-tempo-1-registrationa-5499960d)
- 2026-07-28 12:00 EST — BCLI — [BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman](https://biopharmsignal.com/news/BCLI/brainstorm-appoints-former-fda-associate-commissioner-peter-j-pitts-as-executive-0d7242f8)